Central Data Catalog


Type Journal Article - Clinical Infectious Diseases
Title Antibody persistence at 1 and 4 years following a single dose of MenAfriVac or quadrivalent polysaccharide vaccine in healthy subjects aged 2–29 years
Volume 61
Issue suppl_1
Publication (Day/Month/Year) 2015
Page numbers S521-S530
URL https://doi.org/10.1093/cid/civ518
Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in India and found to be safe and highly immunogenic compared with the group A component of the licensed quadrivalent polysaccharide vaccine (PsACWY). Antibody persistence in Africa and in India was investigated.

Methods. A total of 900 subjects aged 2–29 years were followed up for 4 years in Senegal, Mali, and The Gambia (study A). A total of 340 subjects aged 2–10 years were followed up for 1 year in India (study B). In study A, subjects were randomized in a 2:1 ratio, and in study B a 1:1 ratio to receive either PsA-TT or PsACWY. Immunogenicity was evaluated by measuring MenA serum bactericidal antibody (SBA) with rabbit complement and by a group A–specific immunoglobulin G (IgG) enzyme-linked immunosorbent assay.

Results. In both studies, substantial SBA decay was observed at 6 months postvaccination in both vaccine groups, although more marked in the PsACWY group. At 1 year and 4 years (only for study A) postvaccination, SBA titers were relatively sustained in the PsA-TT group, whereas a slight increasing trend, more pronounced among the youngest, was observed in the participants aged <18 years in the PsACWY groups. The SBA titers were significantly higher in the PsA-TT group than in the PsACWY group at any time point, and the majority of subjects in the PsA-TT group had SBA titers ≥128 and group A–specific IgG concentrations ≥2 µg/mL at any point in time in both the African and Indian study populations.

Conclusions. Four years after vaccination with a single dose of PsA-TT vaccine in Africa, most subjects are considered protected from MenA disease.
Aldiouma Diallo,, Samba O Sow , Olubukola T Idoko , Siddhivinayak Hirve , Helen Findlow , Marie-Pierre Preziosi , Cheryl Elie , Prasad S Kulkarni , Varsha Parulekar , Bou Diarra , Fadima Cheick Haidara, , Fatoumata Diallo , Milagritos Tapia , Adebayo K Akinsola , Richard A Adegbola , Ashish Bavdekar , Sanjay Juvekar , Julie Chaumont , Lionel Martellet , Elisa Marchetti , Marc F LaForce , Brian D Plikaytis , Godwin C Enwere , Yuxiao Tang , Ray Borrow , George Carlone , and Simonetta Viviani. "Antibody persistence at 1 and 4 years following a single dose of MenAfriVac or quadrivalent polysaccharide vaccine in healthy subjects aged 2–29 years." Clinical Infectious Diseases 61, no. suppl_1 (2015): S521-S530.
Powered by Vadu HDSS
Please send data related queries to data_manager@kemhrcvadu.org